Skip Navigation

European Heart Journal 2003 24(14):1279-1281; doi:10.1016/S0195-668X(03)00263-X
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Menon, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menon, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Cardiogenic shock: have we really found the magic potion?

Venu Menon*

Division of Cardiology, University of North Carolina-Chapel Hill Carolina, USA

* Corresponding author. Tel.: +1-919-843-5221; fax: +1-919-966-1743
E-mail address: menon@med.unc.edu

Received 25 April 2003; accepted 30 April 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00193-3for the article to which this editorial refers

The aetiology of cardiogenic shock following an acute myocardial infarction is multi-factorial. It predominantly arises in the setting of a large myocardial infarction that results in diminished stroke volume and a cardiac output that does not meet ensuing demand. Patients with prior myocardial infarction and extensive coronary artery disease are especially vulnerable due to the inability of the remote myocardium to compensate. Strategies to enhance outcome are focused on early definition of coronary anatomy and emergent revascularization while simultaneously providing haemodynamic support with intra-aortic balloon pulsation and vasopressor therapy. The goal of this approach is to restore infarct artery patency, salvage jeopardized myocardium; and prevent irreversible vital end-organ injury. The NHLBI supported SHOCK trial conclusively established the utility of this invasive strategy in a randomized prospective trial.1At 12-months an early revascularization strategyresulted . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock: A prospective randomized study
Gad Cotter, Edo Kaluski, Olga Milo, Alex Blatt, Ahmed Salah, Alberto Hendler, Rikardo Krakover, Ahuva Golick, and Zvi Vered
EHJ 2003 24: 1287-1295. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
G. B. Danzi, L. Mauri, and F. Sozzi
Percutaneous coronary intervention and beyond for ST-elevation acute myocardial infarction
Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K26 - K30.
[Abstract] [Full Text] [PDF]